O-Benzyl-N-[1-(5-fluoro-benzo[b]thiophen-2-yl)-ethyl]-hydroxylamine | 118575-04-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: O-Benzyl-N-[1-(5-fluoro-benzo[b]thiophen-2-yl)-ethyl]-hydroxylamine
• 英文别名: N-benzyloxy-1-(5-fluorobenzo[b]thien-2-yl)ethyl amine；1-(5-fluoro-1-benzothiophen-2-yl)-N-phenylmethoxyethanamine
• CAS: 118575-04-5
• 化学式: C₁₇H₁₆FNOS
• 分子量: 301.385
• InChiKey: GNLFIOAQMQVNFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  49.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  O-Benzyl-N-[1-(5-fluoro-benzo[b]thiophen-2-yl)-ethyl]-hydroxylamine 在 三氯化铝 、 乙硫醇 作用下， 以 二氯甲烷 为溶剂， 生成 1-(5-Fluorobenzo[b]thien-2-yl)ethyl hydroxylamine
  参考文献：
  名称：

  Structure−Activity Relationships of N-Hydroxyurea 5-Lipoxygenase Inhibitors

  摘要：

  The discovery of second generation N-hydroxyurea 5-lipoxygenase inhibitors was accomplished through the development of a broad structure-activity relationship (SAR) study. This study identified requirements for improving potency and also extending duration by limiting metabolism. Potency could be maintained by the incorporation of heterocyclic templates substituted with selected lipophilic substituents. Duration of inhibition after oral administration was optimized by identification of structural features in the proximity of the N-hydroxyurea which correlated to low in vitro glucuronidation rates. Furthermore, the rate of in vitro glucuronidation was shown to be stereoselective for certain analogs. (R)-N-[3-[5-(4-Fluorophenoxy)-2-furyl]-1-methyl-2-propynyl]-N-hy- droxyurea (17c) was identified and selected for clinical development.

  DOI：

  10.1021/jm9700474
• 作为产物：
  描述：

  5-氟苯并[b]噻吩 、 acetaldehyde O-benzyloxime 在 正丁基锂 、 三氟化硼乙醚 作用下， 生成 O-Benzyl-N-[1-(5-fluoro-benzo[b]thiophen-2-yl)-ethyl]-hydroxylamine
  参考文献：
  名称：

  Structure−Activity Relationships of N-Hydroxyurea 5-Lipoxygenase Inhibitors

  摘要：

  The discovery of second generation N-hydroxyurea 5-lipoxygenase inhibitors was accomplished through the development of a broad structure-activity relationship (SAR) study. This study identified requirements for improving potency and also extending duration by limiting metabolism. Potency could be maintained by the incorporation of heterocyclic templates substituted with selected lipophilic substituents. Duration of inhibition after oral administration was optimized by identification of structural features in the proximity of the N-hydroxyurea which correlated to low in vitro glucuronidation rates. Furthermore, the rate of in vitro glucuronidation was shown to be stereoselective for certain analogs. (R)-N-[3-[5-(4-Fluorophenoxy)-2-furyl]-1-methyl-2-propynyl]-N-hy- droxyurea (17c) was identified and selected for clinical development.

  DOI：

  10.1021/jm9700474

文献信息

• Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting
  申请人：Abbott Laboratories

  公开号：US04873259A1

  公开（公告）日：1989-10-10

  Compounds of the formula: ##STR1## wherein R.sub.1 is (1) hydrogen, (2) C.sub.1 to C.sub.4 alkyl, (3) C.sub.2 to C.sub.4 alkenyl, or (4) NR.sub.2 R.sub.3, wherein R.sub.2 and R.sub.3 are independently selected from (1) hydrogen, (2) C.sub.1 to C.sub.4 alkyl and (3) hydroxyl, but R.sub.2 and R.sub.3 are not simultaneously hydroxyl; wherein X is oxygen, sulfur, SO.sub.2, or NR.sub.4, wherein R.sub.4 is (1) hydrogen, (2) C.sub.1 to C.sub.6 alkyl, (3) C.sub.1 to C.sub.6 alkoyl, (4) aroyl, or (5) alkylsulfonyl; A is selected from C.sub.1 to C.sub.6 alkylene and C.sub.2 to C.sub.6 alkenylene; n is 1-5; Y is selected independently at each occurrence from (1) hydrogen, (2) halogen, (3) hydroxy, (4) cyano, (5) halosubstituted alkyl, (6) C.sub.1 to C.sub.12 alkyl, (7) C.sub.2 to C.sub.12 alkenyl, (8) C.sub.1 to C.sub.12 alkoxy, (9) C.sub.3 to C.sub.8 cycloalkyl, (10) C.sub.1 -C.sub.8 thioalkyl, (11) aryl, (12) aryloxy, (13) aroyl, (14) C.sub.1 to C.sub.12 arylalkyl, (15) C.sub.2 to C.sub.12 arylalkenyl, (16) C.sub.1 to C.sub.12 arylalkoxy, (17) C.sub.1 to C.sub.12 arylthioalkoxy, and substituted derivatives of (18) aryl, (19) aryloxy, (20) aroyl, (21) C.sub.1 to C.sub.12 arylalkyl, (22) C.sub.2 to C.sub.12 arylalkenyl, (23) C.sub.1 to C.sub.12 arylalkoxy, or (24) C.sub.1 to C.sub.12 arylthioalkoxy, wherein substituents are selected from halo, nitro, cyano, C.sub.1 to C.sub.12 alkyl, alkoxy, and halosubstituted alkyl; Z is oxygen or sulfur; and M is hydrogen, a pharmaceutically acceptable cation, aroyl, or C.sub.1 to C.sub.12 alkoyl, are potent inhibitors of 5- and/or 12-lipoxygenase enzymes. Also disclosed are lipoxygenase inhibiting compositions and a method for inhibiting lipoxygenase activity.

  该公式的化合物：##STR1##其中R.sub.1是（1）氢，（2）C.sub.1到C.sub.4烷基，（3）C.sub.2到C.sub.4烯基或（4）NR.sub.2R.sub.3，其中R.sub.2和R.sub.3分别选择自（1）氢，（2）C.sub.1到C.sub.4烷基和（3）羟基，但R.sub.2和R.sub.3不能同时为羟基；其中X是氧，硫，SO.sub.2或NR.sub.4，其中R.sub.4是（1）氢，（2）C.sub.1到C.sub.6烷基，（3）C.sub.1到C.sub.6烷酰基，（4）芳酰基或（5）烷基磺酰基；A选择自C.sub.1到C.sub.6烷基和C.sub.2到C.sub.6烯基；n为1-5；Y每次独立选择自（1）氢，（2）卤素，（3）羟基，（4）氰基，（5）卤代烷基，（6）C.sub.1到C.sub.12烷基，（7）C.sub.2到C.sub.12烯基，（8）C.sub.1到C.sub.12烷氧基，（9）C.sub.3到C.sub.8环烷基，（10）C.sub.1-C.sub.8硫代烷基，（11）芳基，（12）芳氧基，（13）芳酰基，（14）C.sub.1到C.sub.12芳基烷基，（15）C.sub.2到C.sub.12芳基烯基，（16）C.sub.1到C.sub.12芳基烷氧基，（17）C.sub.1到C.sub.12芳基硫代烷氧基，以及取代衍生物的（18）芳基，（19）芳氧基，（20）芳酰基，（21）C.sub.1到C.sub.12芳基烷基，（22）C.sub.2到C.sub.12芳基烯基，（23）C.sub.1到C.sub.12芳基烷氧基或（24）C.sub.1到C.sub.12芳基硫代烷氧基，其中取代基选择自卤素，硝基，氰基，C.sub.1到C.sub.12烷基，烷氧基和卤代烷基；Z是氧或硫；M是氢，药学上可接受的阳离子，芳酰基或C.sub.1到C.sub.12烷酰基，是5-和/或12-脂氧合酶酶的有效抑制剂。还公开了抑制脂氧合酶活性的脂氧合酶抑制剂组合物和方法。
• Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
  申请人：ABBOTT LABORATORIES

  公开号：EP0279263B1

  公开（公告）日：1993-08-04
• US4873259A
  申请人：——

  公开号：US4873259A

  公开（公告）日：1989-10-10
• Structure−Activity Relationships of <i>N</i>-Hydroxyurea 5-Lipoxygenase Inhibitors
  作者：Andrew O. Stewart、Pramila A. Bhatia、Jonathan G. Martin、James B. Summers、Karen E. Rodriques、Michael B. Martin、James H. Holms、Jimmie L. Moore、Richard A. Craig、Teodozyj Kolasa、James D. Ratajczyk、Hormoz Mazdiyasni、Francis A. J. Kerdesky、Shari L. DeNinno、Robert G. Maki、Jennifer B. Bouska、Patrick R. Young、Carmine Lanni、Randy L. Bell、George W. Carter、Clint D. W. Brooks

  DOI：10.1021/jm9700474

  日期：1997.6.1

  The discovery of second generation N-hydroxyurea 5-lipoxygenase inhibitors was accomplished through the development of a broad structure-activity relationship (SAR) study. This study identified requirements for improving potency and also extending duration by limiting metabolism. Potency could be maintained by the incorporation of heterocyclic templates substituted with selected lipophilic substituents. Duration of inhibition after oral administration was optimized by identification of structural features in the proximity of the N-hydroxyurea which correlated to low in vitro glucuronidation rates. Furthermore, the rate of in vitro glucuronidation was shown to be stereoselective for certain analogs. (R)-N-[3-[5-(4-Fluorophenoxy)-2-furyl]-1-methyl-2-propynyl]-N-hy- droxyurea (17c) was identified and selected for clinical development.